JP2022537555A5 - - Google Patents

Info

Publication number
JP2022537555A5
JP2022537555A5 JP2021575397A JP2021575397A JP2022537555A5 JP 2022537555 A5 JP2022537555 A5 JP 2022537555A5 JP 2021575397 A JP2021575397 A JP 2021575397A JP 2021575397 A JP2021575397 A JP 2021575397A JP 2022537555 A5 JP2022537555 A5 JP 2022537555A5
Authority
JP
Japan
Prior art keywords
patient
smrt
ncor2
mutation
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021575397A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/038643 external-priority patent/WO2020257586A2/en
Publication of JP2022537555A publication Critical patent/JP2022537555A/ja
Publication of JP2022537555A5 publication Critical patent/JP2022537555A5/ja
Pending legal-status Critical Current

Links

JP2021575397A 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法 Pending JP2022537555A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962864404P 2019-06-20 2019-06-20
US62/864,404 2019-06-20
US201962867172P 2019-06-26 2019-06-26
US62/867,172 2019-06-26
PCT/US2020/038643 WO2020257586A2 (en) 2019-06-20 2020-06-19 Method of treatment with viral-based gene therapy

Publications (2)

Publication Number Publication Date
JP2022537555A JP2022537555A (ja) 2022-08-26
JP2022537555A5 true JP2022537555A5 (https=) 2023-06-23

Family

ID=71579659

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021575397A Pending JP2022537555A (ja) 2019-06-20 2020-06-19 ウイルスベースの遺伝子療法による治療方法

Country Status (5)

Country Link
US (1) US20200405883A1 (https=)
EP (1) EP3986481A2 (https=)
JP (1) JP2022537555A (https=)
CN (1) CN114375205A (https=)
WO (1) WO2020257586A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114277057B (zh) * 2021-07-09 2023-10-13 上海天泽云泰生物医药有限公司 用于治疗或预防b型血友病的重组腺相关病毒载体和方法
CN115772214B (zh) * 2022-11-30 2023-09-29 湖南家辉生物技术有限公司 F8突变体蛋白、f8基因突变体、检测f8基因突变体的引物组合、试剂及应用
TW202444398A (zh) * 2023-01-09 2024-11-16 美商拜奧馬林製藥公司 表觀遺傳修飾劑改善aav基因療法之耐久性

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795965A (en) 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
US5831005A (en) 1992-09-24 1998-11-03 Chiron Corporation Synthesis of N-substituted oligomers
US5877278A (en) 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US6531298B2 (en) 1997-07-21 2003-03-11 The University Of North Carolina At Chapel Hill Factor IX antihemophilic factor with increased clotting activity
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
PT2308888T (pt) 2001-11-14 2017-05-03 Janssen Biotech Inc Anticorpos anti-il-6, composições, métodos e utilizações
JO3058B1 (ar) 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
ATE550353T1 (de) 2005-12-30 2012-04-15 Merck Patent Gmbh Die bindung von mit il-6ralpha komplexiertem il-6 an gp130 verhindernde anti-il-6-antikörper
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトil−6受容体に対する高親和性抗体
CN101563365B (zh) 2006-08-03 2012-10-31 瓦西尼斯公司 抗-il-6单克隆抗体及其用途
WO2008069942A2 (en) 2006-12-05 2008-06-12 Biogen Idec Ma Inc. Novel methods of enhancing delivery of a gene therapy vector using steroids
MX2010012031A (es) 2008-05-13 2011-01-20 Novimmune Sa Anticuerpos anti-il-6/il-6r y metodos de uso de los mismos.
MX2011000071A (es) 2008-07-02 2011-05-03 Emergent Product Dev Seattle Inmunoterapeuticos de interleucina-6 (il6).
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
AU2009313958B2 (en) 2008-11-13 2015-09-10 Femta Pharmaceuticals, Inc. Humanized anti-IL-6 antibodies
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
WO2011031657A1 (en) 2009-09-08 2011-03-17 Centocor Ortho Biotech Inc. Use of an anti-il6 antibody to decrease hepcidin in cancer patients
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
EP2640745B1 (en) 2010-09-10 2018-11-07 MedImmune Limited Bivalent and bispecific anti-il6/anti-il23 antibodies
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
EP3204503A1 (en) * 2014-10-06 2017-08-16 Arthrogen BV Aav-based gene therapy
EP3283126B1 (en) * 2015-04-16 2019-11-06 Emory University Recombinant promoters and vectors for protein expression in liver and use thereof
CA2991637C (en) * 2015-07-31 2022-07-05 Medimmune Limited Methods for treating hepcidin-mediated disorders
TW202446416A (zh) * 2015-09-24 2024-12-01 美商拜奧馬林製藥公司 腺相關病毒因子viii載體、相關病毒粒子及包含其之治療調配物
WO2017079443A1 (en) 2015-11-03 2017-05-11 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
EA202190827A1 (ru) * 2015-11-13 2021-11-30 Баксалта Инкорпорейтед Вирусные векторы, кодирующие рекомбинантные варианты fviii с повышенной экспрессией для генной терапии гемофилии a
CA3005565A1 (en) * 2015-11-13 2017-05-18 Baxalta Incorporated Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
WO2018029182A1 (en) 2016-08-08 2018-02-15 Ablynx N.V. Il-6r single variable domain antibodies for treatment of il-6r related diseases
WO2018112237A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
MX2019008143A (es) * 2017-01-07 2020-01-13 Selecta Biosciences Inc Dosificación sistemática de inmunosupresores acoplados a nanoportadores sintéticos.
KR20200012823A (ko) * 2017-02-01 2020-02-05 예일 유니버시티 이뇨제 내성의 치료
US11617797B2 (en) * 2017-04-28 2023-04-04 David T. Tran Multi-targeted multi-valent ligand drug particles for the treatment and prevention of diseases and conditions
CN110945127B (zh) 2017-05-22 2024-07-12 武田药品工业株式会社 用于血友病b的基因疗法的编码具有增加的表达的重组fix的病毒载体
CN111051343B (zh) 2017-09-13 2022-11-22 江苏恒瑞医药股份有限公司 Il-6r抗体、其抗原结合片段及医药用途
CN109867723B (zh) 2017-12-05 2022-06-17 南京金斯瑞生物科技有限公司 抗人il6单克隆抗体及其制备方法和用途

Similar Documents

Publication Publication Date Title
JP2022537555A5 (https=)
Martinet et al. Differential expression of the tumor necrosis factor/cachectin gene by blood and lung mononuclear phagocytes
AU2019243283A1 (en) Methods of treating ulcerative colitis
JPH02304027A (ja) 前新生物性病変の全身的治療のための少なくとも1種のサイトカインを含む製剤組成物の使用
CN113559107B (zh) 孕激素在制备抑制细胞因子风暴的药物中的应用
JP2021534201A5 (https=)
JP2024515459A5 (https=)
Sauer et al. Inhibition of lipopolysaccharide-induced monocyte interleukin-1 receptor antagonist synthesis by cortisol: involvement of the mineralocorticoid receptor
Lemaitre et al. The effects of intraocular injection of interleukin-13 on endotoxin-induced uveitis in rats
US6124257A (en) Method of treatment
JP2024531314A5 (https=)
Tanihara et al. Tumor necrosis factor-α gene is expressed in stimulated retinal pigment epithelial cells in culture
JP2022537555A (ja) ウイルスベースの遺伝子療法による治療方法
JP2023513487A5 (https=)
US20210386821A1 (en) Therapeutic composition for use in the treatment of covid-19 and other cytokine storm associated disorders
WO2025102927A1 (zh) 一种清除IgG/IgM抗体或B细胞药物的应用
JP3568208B2 (ja) 弱毒化された非免疫原性ポックスウイルスまたはパラポックスウイルスからの多種有効性パラポックス免疫誘導剤の薬剤としての使用のための新規薬効
EP3849603A1 (en) Methods of treating psoriasis
CN115813933A (zh) Fasudil在制备治疗COVID-19引起的细胞因子风暴的药物组合物中的应用
RU2469737C1 (ru) Способ лечения хронического риносинусита
Carty et al. Decreased IL-6 secretion by fibroblasts following repeated doses of TNFα or IL-1α: Post-transcriptional gene regulation
WO2021004229A1 (zh) 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用
Fiers et al. Gene cloning and structure-function relationship of cytokines such as TNF and interleukins
CN114288314A (zh) 克拉屈滨在制备用于预防或治疗银屑病药物中的用途
Hong et al. Loss of ATF3 exacerbates pulmonary fibrosis via enhanced neutrophil recruitment and profibrotic macrophage polarization